Physician profile
Amy M Jackson
NPI 1033155106
$6,843.70
in general payments reported to CMS, 2019-2025
37 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $913 · 2021: $772 · 2022: $599 · 2023: $1,664 · 2024: $1,411 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,106.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $926.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $841.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $680.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $653.01 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.45 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $415.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $410.49 | 2019-2024 | Spravato |
| Exact Sciences Corporation | $386.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $310.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $252.60 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $160.57 | 2023-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $125.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $114.57 | 2019-2024 | Gardasil 9, Gardasil |
| Abbott Laboratories | $109.58 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $108.61 | 2023-2025 | Quviviq, Quviviq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $93.85 | 2021-2024 | Immunocap |
| Daiichi Sankyo INC. | $86.69 | 2019-2022 | |
| Amarin Pharma, INC. | $75.71 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $60.57 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $59.74 | 2020-2025 | Contrave |
| Novartis Pharmaceuticals Corporation | $52.44 | 2019-2022 | |
| Gilead Sciences, INC. | $44.87 | 2020 | |
| Dynavax Technologies Corporation | $41.81 | 2021-2025 | Heplisav-B |
| Upsher-Smith Laboratories LLC | $40.00 | 2020-2021 | |
| Sanofi Pasteur INC. | $38.09 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.96 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $34.52 | 2020-2021 | |
| Hologic Sales and Service, LLC | $28.38 | 2025 | Aptima |
| Dexcom, INC. | $25.13 | 2024 | Dexcom G6 Transmitter |
| Nalpropion Pharmaceuticals LLC | $23.50 | 2019 | |
| Bausch Health US, LLC | $20.78 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.62 | 2022 | |
| Dermira, INC. | $14.54 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.01 | 2019 | |
| Neuronetics, INC. | $13.93 | 2020 | |
| Eisai INC. | $13.60 | 2021 | |
| Allergan, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.